Floatz logo

Cyclophosphamide

Prostate Carcinoma

OHSU Knight Cancer InstituteSmall moleculePhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
81/ 100

Competitive context

47 Active assets in the Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
Psma-Hbed-Cc
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3BB
Olaparib
OHSU Knight Cancer Institute
Phase 2BB
CABAZITAXEL
M.D. Anderson Cancer Center
Phase 2B
Veliparib
National Cancer Institute (NCI)
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →